65 related articles for article (PubMed ID: 31845840)
1. Association between Postoperative Detection of Circulating Tumor Cells and Recurrence in Patients with Prostate Cancer.
Pak S; Suh YS; Lee DE; Kim SH; Joung JY; Park WS; Lee SJ; Lee KH
J Urol; 2020 Jun; 203(6):1128-1134. PubMed ID: 31845840
[TBL] [Abstract][Full Text] [Related]
2. Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy.
Hoey C; Ahmed M; Fotouhi Ghiam A; Vesprini D; Huang X; Commisso K; Commisso A; Ray J; Fokas E; Loblaw DA; He HH; Liu SK
J Transl Med; 2019 May; 17(1):173. PubMed ID: 31122242
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD105 is prognostic of disease recurrence in prostate cancer patients.
Placencio-Hickok VR; Madhav A; Kim S; Duong F; Angara B; Liu Z; Bhowmick NA
Endocr Relat Cancer; 2020 Jan; 27(1):1-9. PubMed ID: 31648185
[TBL] [Abstract][Full Text] [Related]
4. Persistent Circulating Tumor Cells at 1 Year After Oncologic Resection Predict Late Recurrence in Pancreatic Cancer.
Javed AA; Ding D; Hasanain A; van Oosten F; Yu J; Cameron JL; Burkhart RA; Zheng L; He J; Wolfgang CL
Ann Surg; 2023 Jun; 277(6):859-865. PubMed ID: 36111892
[TBL] [Abstract][Full Text] [Related]
5. Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer.
Pope B; Park G; Lau E; Belic J; Lach R; George A; McCoy P; Nguyen A; Grima C; Campbell B; Jung CH; Ditter EJ; Zhao H; ; Wedge DC; Brewer DS; Lynch AG; Dev H; Gnanpragasam VJ; Rosenfeld N; Hovens CM; Corcoran NM; Massie CE
Eur Urol; 2024 Apr; 85(4):407-410. PubMed ID: 38378299
[No Abstract] [Full Text] [Related]
6. Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients.
Galizia G; Gemei M; Orditura M; Romano C; Zamboli A; Castellano P; Mabilia A; Auricchio A; De Vita F; Del Vecchio L; Lieto E
J Gastrointest Surg; 2013 Oct; 17(10):1809-18. PubMed ID: 23813048
[TBL] [Abstract][Full Text] [Related]
7. Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer.
Liu S; Shen M; Hsu EC; Zhang CA; Garcia-Marques F; Nolley R; Koul K; Rice MA; Aslan M; Pitteri SJ; Massie C; George A; Brooks JD; Gnanapragasam VJ; Stoyanova T
Br J Cancer; 2021 Mar; 124(5):896-900. PubMed ID: 33288843
[TBL] [Abstract][Full Text] [Related]
8. Correlations of glycolipid metabolism abnormality and insulin resistance with the onset of prostate cancer and its postoperative recurrence.
Liu Y; Teng Z; Zhao L; Yue M; Cheng B
Panminerva Med; 2019 Oct; ():. PubMed ID: 31670492
[No Abstract] [Full Text] [Related]
9. Circulating Tumor Cells for Cancer Management.
Pierga JY
Clin Chem; 2019 Oct; ():. PubMed ID: 31672852
[No Abstract] [Full Text] [Related]
10. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS; Lawrentschuk N; Francis RJ; Tang C; Vela I; Thomas P; Rutherford N; Martin JM; Frydenberg M; Shakher R; Wong LM; Taubman K; Ting Lee S; Hsiao E; Roach P; Nottage M; Kirkwood I; Hayne D; Link E; Marusic P; Matera A; Herschtal A; Iravani A; Hicks RJ; Williams S; Murphy DG;
Lancet; 2020 Apr; 395(10231):1208-1216. PubMed ID: 32209449
[TBL] [Abstract][Full Text] [Related]
11. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity - United States, 2001-2017.
Siegel DA; O'Neil ME; Richards TB; Dowling NF; Weir HK
MMWR Morb Mortal Wkly Rep; 2020 Oct; 69(41):1473-1480. PubMed ID: 33056955
[TBL] [Abstract][Full Text] [Related]
12. Anesthesia and Circulating Tumor Cells in Primary Breast Cancer Patients: A Randomized Controlled Trial.
Hovaguimian F; Braun J; Z'graggen BR; Schläpfer M; Dumrese C; Ewald C; Dedes KJ; Fink D; Rölli U; Seeberger M; Tausch C; Papassotiropoulos B; Puhan MA; Beck-Schimmer B
Anesthesiology; 2020 Sep; 133(3):548-558. PubMed ID: 32568845
[TBL] [Abstract][Full Text] [Related]
13. [
Alemozaffar M; Akintayo AA; Abiodun-Ojo OA; Patil D; Saeed F; Huang Y; Osunkoya AO; Goodman MM; Sanda M; Schuster DM
J Urol; 2020 Oct; 204(4):734-740. PubMed ID: 32347780
[TBL] [Abstract][Full Text] [Related]
14. Reconsidering Prostate Cancer Mortality - The Future of PSA Screening.
Welch HG; Albertsen PC
N Engl J Med; 2020 Apr; 382(16):1557-1563. PubMed ID: 32294352
[No Abstract] [Full Text] [Related]
15. Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on
Markowski MC; Sedhom R; Fu W; Gray JCR; Eisenberger MA; Pomper MG; Pienta KJ; Gorin MA; Rowe SP
J Urol; 2020 Sep; 204(3):496-502. PubMed ID: 32250727
[TBL] [Abstract][Full Text] [Related]
16. Optimal Timing of Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Biochemical Recurrence after Radical Prostatectomy.
Luiting HB; van Leeuwen PJ; Remmers S; Donswijk M; Busstra MB; Bakker IL; Brabander T; Stokkel M; van der Poel HG; Roobol MJ
J Urol; 2020 Sep; 204(3):503-510. PubMed ID: 32149575
[TBL] [Abstract][Full Text] [Related]
17. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.
Ahdoot M; Wilbur AR; Reese SE; Lebastchi AH; Mehralivand S; Gomella PT; Bloom J; Gurram S; Siddiqui M; Pinsky P; Parnes H; Linehan WM; Merino M; Choyke PL; Shih JH; Turkbey B; Wood BJ; Pinto PA
N Engl J Med; 2020 Mar; 382(10):917-928. PubMed ID: 32130814
[TBL] [Abstract][Full Text] [Related]
18. Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer.
Lin J; Den RB; Greenspan J; Showalter TN; Hoffman-Censits JH; Lallas CD; Trabulsi EJ; Gomella LG; Hurwitz MD; Leiby B; Dicker AP; Kelly WK
Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):939-947. PubMed ID: 32029346
[TBL] [Abstract][Full Text] [Related]
19. [Enzalutamide-new option in metastatic castration-sensitive prostate cancer? : Preliminary results of a randomized phase III trial (ENZAMET)].
Boegemann M
Urologe A; 2020 Jan; 59(1):78-79. PubMed ID: 31853892
[No Abstract] [Full Text] [Related]
20. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma.
Ahn JC; Teng PC; Chen PJ; Posadas E; Tseng HR; Lu SC; Yang JD
Hepatology; 2021 Jan; 73(1):422-436. PubMed ID: 32017145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
